Cost effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom using a decision-analytic health economic model.
L
L
Anderson
A J
AJ
Lockwood
S
S
Goverdhan
R
R
Wormald
J F
JF
Kirwan
D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005901:Glaucoma / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D000077338:Latanoprost; D008390:Markov Chains; D011461:Prostaglandins F, Synthetic / Q000191:economics* / Q000627:therapeutic use; D012537:Scandinavian and Nordic Countries; D013999:Timolol / Q000191:economics* / Q000627:therapeutic use; D006113:United Kingdom
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol